Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd (NQ: ENLV )

1.140 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30,821
Open 1.170
Bid (Size) 1.090 (8)
Ask (Size) 1.150 (2)
Prev. Close 1.140
Today's Range 1.101 - 1.170
52wk Range 0.8101 - 4.590
Shares Outstanding 18,306,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
Via ACCESSWIRE
Enlivex Adopts Bitcoin Treasury Reserve Strategy
From Enlivex Therapeutics Ltd
Via GlobeNewswire

Performance

YTD
-65.45%
-65.45%
1 Month
-15.56%
-15.56%
3 Month
-9.52%
-9.52%
6 Month
-22.45%
-22.45%
1 Year
-36.67%
-36.67%

More News

Read More
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Via ACCESSWIRE
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV)
Via AB Newswire
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Nasdaq Jumps 250 Points; Crude Oil Down 1%
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.